Anika maintains 2025 revenue ranges by channel as follows: Commercial Channel, unchanged, of $47 to $49.5 million, up 12% to 18% year over year; OEM Channel, unchanged, of $62 to $65 million, down 16% to 20% year over year. Anika maintains Adjusted EBITDA as a percent of revenue of positive 3% to negative 3%.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANIK:
- Anika Therapeutics reports Q3 adjusted EPS 4c vs. 7c last year
- Is ANIK a Buy, Before Earnings?
- Anika Therapeutics’ Integrity Implant System Study: A Market Game Changer?
- Anika Therapeutics: Undervalued Stock with Potential Upside Amidst Execution Challenges